Literature DB >> 22234941

Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis.

Tae-Jin Song1, Yuman Fong, Sung-Jin Cho, Mithat Gönen, Michael Hezel, Scott Tuorto, Sang-Yong Choi, Young-Chul Kim, Sung-Ock Suh, Bum-Hwan Koo, Yang-Seok Chae, William R Jarnagin, David S Klimstra.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Although some epidemiologic and etiologic differences between Asian and Western HCC are known, detailed comparative studies with pathologic correlations have not been performed.
METHODS: Paraffin sections of resected HCC specimens from Memorial Sloan-Kettering Cancer Center and Korea University Medical Center were used to construct tissue microarrays. Immunohistochemical staining of microarray sections was performed using antibodies against markers of proliferation and regulators of cell cycle. Patient data were correlated with staining results.
RESULTS: When comparing both cohorts, significant differences were found in expression of p53 and MDM2. In the Asian group, more frequent positive staining for p53 (24%) was observed compared with the American group (9%; P = 0.037). For MDM2, 26% of American cases stained positive compared with 2% of Asian cases (P = 0.0003). No significant differences were found in expression of Ki67, p21, p27, cyclin D1, or bcl2. Female gender, vascular invasion, and lack of viral hepatitis infection correlated with positive MDM2 staining.
CONCLUSION: These data likely correlate with differences in molecular pathogenesis of HCC based on racial and regional differences. These findings may have implications in choice of molecular targeted therapies based on patient ethnicity.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234941      PMCID: PMC3346847          DOI: 10.1002/jso.23036

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  35 in total

1.  p53 gene mutations are not required for early dissemination of cancer cells.

Authors:  S Offner; W Schmaus; K Witter; G B Baretton; G Schlimok; B Passlick; G Riethmüller; K Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 2.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

3.  Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells.

Authors:  S L Friedman; E Shaulian; T Littlewood; D Resnitzky; M Oren
Journal:  Oncogene       Date:  1997-07-03       Impact factor: 9.867

Review 4.  Current status of hepatitis C virus infection in Korea.

Authors:  Dong Jin Suh; Sook-Hyang Jeong
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

Review 5.  Regulation of p53 downstream genes.

Authors:  W S el-Deiry
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

6.  A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.

Authors:  M Jablkowski; A Bocian; J Bialkowska; J Bartkowiak
Journal:  J Exp Clin Cancer Res       Date:  2005-03

Review 7.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 8.  Epidemiology of hepatitis B and C viruses: a global overview.

Authors:  Helen S Te; Donald M Jensen
Journal:  Clin Liver Dis       Date:  2010-02       Impact factor: 6.126

Review 9.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

Review 10.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

View more
  12 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.

Authors:  Shao-Hua Ren; Zi-Lin Cui; Meng-Ran Lang; Qiang Li; Wei Zhang; Feng Fang; Qiang Wu; Yun-Long Cui; Hui-Kai Li; Ping Chen; Yamin Zhang; Tianqiang Song
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Asian American/Pacific Islander and Hispanic Ethnic Enclaves, Neighborhood Socioeconomic Status, and Hepatocellular Carcinoma Incidence in California: An Update.

Authors:  Meera Sangaramoorthy; Juan Yang; Alice Guan; Mindy C DeRouen; Michele M Tana; Ma Somsouk; Caroline A Thompson; Joseph Gibbons; Chanda Ho; Janet N Chu; Iona Cheng; Scarlett Lin Gomez; Salma Shariff-Marco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-30       Impact factor: 4.090

Review 4.  Progress in systemic therapy of advanced hepatocellular carcinoma.

Authors:  Xin-Lei Gong; Shu-Kui Qin
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

5.  TOP2A amplification and overexpression in hepatocellular carcinoma tissues.

Authors:  Ravat Panvichian; Anchalee Tantiwetrueangdet; Napat Angkathunyakul; Surasak Leelaudomlipi
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

6.  Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma.

Authors:  Mei Liu; Su-jun Zheng; Yu Chen; Ning Li; Peng-fei Ren; Li-ping Dai; Zhong-ping Duan; Jian-Ying Zhang
Journal:  J Immunol Res       Date:  2014-05-14       Impact factor: 4.818

Review 7.  Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA).

Authors:  Luca Quagliata; Manuel Schlageter; Cristina Quintavalle; Luigi Tornillo; Luigi M Terracciano
Journal:  Microarrays (Basel)       Date:  2014-04-15

8.  Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis.

Authors:  Jing Peng; Jing-Jin Li; Jiang Li; He-Wen Li; Guo-Ping Xu; Rong-Rong Jia; Xue-Ning Zhang; Yang Zhao
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

9.  Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma.

Authors:  Gu Hyum Kang; Byung Seok Lee; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee; Dae Young Kang
Journal:  Gut Liver       Date:  2014-01-13       Impact factor: 4.519

10.  Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Mark Christiaan Burgmans; Chow Wei Too; Marta Fiocco; Annarein J C Kerbert; Richard Hoau Gong Lo; Jelte J Schaapman; Arian R van Erkel; Minneke J Coenraad; Bien Soo Tan
Journal:  Cardiovasc Intervent Radiol       Date:  2016-09-26       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.